Cardiff Oncology, Inc. (CRDF) › Net IncomeCardiff Oncology, Inc. (CRDF) — Net IncomeAnnual figures by fiscal year, from SEC filings.2001: -$267.6K2002: -$524.2K2003: -$481.6K2004: -$383.0K2005: -$5.37M2006: -$7.84M2007: -$7.13M2008: -$5.17M2009: -$2.48M2010: -$5.45M2011: -$2.24M2012: -$11.57M2013: -$11.81M2014: -$14.33M2015: -$27.47M2016: -$39.20M2017: -$24.91M2018: -$16.46M2019: -$16.41M2020: -$19.31M2021: -$28.29M2022: -$38.70M2023: -$41.44M2024: -$45.43M2025: -$45.85M-$45.85M2001Net Income (USD)2025Fiscal YearNet IncomeChange YoY2025-$45.85M-0.9%2024-$45.43M-9.6%2023-$41.44M-7.1%2022-$38.70M-36.8%2021-$28.29M-46.5%2020-$19.31M-17.6%2019-$16.41M+0.3%2018-$16.46M+33.9%2017-$24.91M+36.5%2016-$39.20M-42.7%2015-$27.47M-91.8%2014-$14.33M-21.3%2013-$11.81M-2.1%2012-$11.57M-416.5%2011-$2.24M+58.9%2010-$5.45M-119.4%2009-$2.48M+51.9%2008-$5.17M+27.6%2007-$7.13M+9.1%2006-$7.84M-46.0%2005-$5.37M-1302.3%2004-$383.0K+20.5%2003-$481.6K+8.1%2002-$524.2K-95.9%2001-$267.6K—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share